Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:NEO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.63-2.5%$7.24$4.73▼$9.53$703.03M0.39471,363 shs347,125 shsNEONeoGenomics$10.90-3.6%$8.70$4.72▼$13.74$1.47B1.821.31 million shs1.05 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-1.16%-9.33%-23.60%+21.43%+10.75%NEONeoGenomics+11.54%+10.99%+27.65%+26.23%+53.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.63-2.5%$7.24$4.73▼$9.53$703.03M0.39471,363 shs347,125 shsNEONeoGenomics$10.90-3.6%$8.70$4.72▼$13.74$1.47B1.821.31 million shs1.05 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-1.16%-9.33%-23.60%+21.43%+10.75%NEONeoGenomics+11.54%+10.99%+27.65%+26.23%+53.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.25Hold$20.50209.20% UpsideNEONeoGenomics 2.42Hold$13.8627.13% UpsideCurrent Analyst Ratings BreakdownLatest YCA, BKY, AURA, and NEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026NEONeoGenomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026AURAAura Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.004/29/2026NEONeoGenomics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$11.004/29/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $24.004/29/2026NEONeoGenomics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $14.004/29/2026NEONeoGenomics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$12.00 ➝ $25.003/30/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.003/27/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026NEONeoGenomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/16/2026NEONeoGenomics William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/ANEONeoGenomics$727.33M1.95$0.32 per share33.76$6.47 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$106.19M-$1.74N/AN/AN/AN/A-78.12%-64.08%8/12/2026 (Estimated)NEONeoGenomics-$108.03M-$0.77N/A363.33N/A-13.30%-2.80%-1.72%8/4/2026 (Estimated)Latest YCA, BKY, AURA, and NEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/11/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A4/28/2026Q1 2026NEONeoGenomics$0.0058$0.01+$0.0042-$0.13$184.54 million$186.67 million3/30/2026Q4 2025AURAAura Biosciences-$0.43-$0.37+$0.06-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ANEONeoGenomicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A7.097.09NEONeoGenomics0.414.424.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%NEONeoGenomics98.50%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences6.30%NEONeoGenomics1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences50103.39 million96.87 millionNot OptionableNEONeoGenomics2,500130.21 million128.78 millionOptionableYCA, BKY, AURA, and NEO HeadlinesRecent News About These CompaniesNeoGenomics (NASDAQ:NEO) Stock Passes Below 200 Day Moving Average - Here's What HappenedJune 3 at 3:02 AM | americanbankingnews.comNeoGenomics Inc (NEO) Stock Up 6.5% and Still Undervalued -- GF Score: 68/100May 28, 2026 | gurufocus.comIs NeoGenomics (NEO) Using Its ASCO ctDNA Focus To Redefine Its Precision Oncology Edge?May 28, 2026 | finance.yahoo.comNeoGenomics to Present New Research at ASCO Annual Meeting 2026May 26, 2026 | finance.yahoo.comNeoGenomics Shareholders Approve Expanded Equity Incentive PlanMay 22, 2026 | tipranks.comNeo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common SharesMay 20, 2026 | globenewswire.comNeo Partners with Greenland Mines to Advance Sarfartoq Rare Earth ProjectMay 20, 2026 | globenewswire.comNeoGenomics to Participate in Upcoming Investor ConferencesMay 15, 2026 | businesswire.comCourt Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomicsMay 14, 2026 | businesswire.comNeoGenomics stock plunges more than 20% as CEO departs after disappointing quarterMay 14, 2026 | marketwatch.comNeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Hold" by BrokeragesMay 9, 2026 | marketbeat.comA Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology IntegrationMay 1, 2026 | finance.yahoo.comNEO Q1 deep dive: High-value test expansion and commercial execution drive oncology growthApril 30, 2026 | msn.comLeerink Partners upgrades NeoGenomics (NEO)April 30, 2026 | msn.comNeoGenomics Inc (NEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...April 30, 2026 | finance.yahoo.comNeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On RevenueApril 30, 2026 | finance.yahoo.comNeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approvalApril 30, 2026 | seekingalpha.comNeoGenomics, Inc. (NEO) Q1 2026 Earnings Call TranscriptApril 29, 2026 | seekingalpha.comNeoGenomics, Inc. 2026 Q1 - Results - Earnings Call PresentationApril 28, 2026 | seekingalpha.comNeoGenomics Reports First Quarter 2026 ResultsApril 28, 2026 | businesswire.comAll eyes on NeoGenomics earnings amid volume growth questionsApril 28, 2026 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIs Backblaze the Next Momentum Monster?By Jeffrey Neal Johnson | May 7, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy?By Sam Quirke | May 15, 2026Shake Shack Stock Gets Shaken After Earnings MissBy Jennifer Ryan Woods | May 12, 2026A Real Biggie Deal: Wendy's Serves Up a Juicy Buyout ArbitrageBy Jeffrey Neal Johnson | May 13, 2026YCA, BKY, AURA, and NEO Company DescriptionsAura Biosciences NASDAQ:AURA$6.63 -0.17 (-2.50%) Closing price 04:00 PM EasternExtended Trading$6.62 0.00 (-0.08%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.NeoGenomics NASDAQ:NEO$10.90 -0.41 (-3.63%) Closing price 04:00 PM EasternExtended Trading$10.90 +0.00 (+0.05%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
